Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Yasuyuki Ikezawa"'
Autor:
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Background Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death‐ligand 1 (PD‐L1) expression is an important is
Externí odkaz:
https://doaj.org/article/9abe2da6e7c64c909348f0fdd32c3056
Autor:
Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line th
Externí odkaz:
https://doaj.org/article/30fdf5599db64195b591b2c71f3f2250
Autor:
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Mototsugu Shimokawa, Satoshi Oizumi
Publikováno v:
Cancer Science. 113:2109-2117
It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected for patients with advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (tumor proportion scor
Autor:
Noriaki Sukoh, Osamu Honjo, Yasuyuki Ikezawa, Hisashi Tanaka, Atsushi Nakamura, Ryoichi Honda, Hiroshi Isobe, Gaku Yamamoto, Ryo Morita, Hajime Asahina, Kenichiro Ito, Hirotoshi Akita, Takaaki Sasaki, Nozomu Kimura, Hajime Kikuchi, Keiki Yokoo, Toshiyuki Sumi, Satoshi Oizumi, Toshiyuki Harada, Yuka Fujita, Taichi Takashina, Hirotoshi Dosaka-Akita, Fumihiro Hommura
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
Scientific Reports
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for
Publikováno v:
Haigan. 61:412-416
Publikováno v:
Haigan. 61:310-314
Publikováno v:
Molecular and Clinical Oncology
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare type of lung cancer, accounting for 3% of all lung cancers. The prognosis is poor and the standard therapy has not been well established. Herein, we report a case of advanced LCNEC of th
Autor:
Shingo Matsumoto, Ryohei Yoshida, Naofumi Shinagawa, Hidenori Mizugaki, Shinichi Chiba, Yutaka Hatanaka, Hidenori Kitai, Yasuyuki Ikezawa, Jun Sakakibara-Konishi, Takaaki Sasaki, Koichi Goto
Publikováno v:
Clinical lung cancer. 20(5):E555-E559
Autor:
Yasuo Kitamura, Hidenori Mizugaki, Yasuyuki Ikezawa, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Satoshi Oizumi
Publikováno v:
Annals of Oncology. 33:S524
Publikováno v:
Open Journal of Nursing. :1226-1239
Purposes: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert satisfactory therapeutic effects in lung cancer patients. However, the resultant skin toxicity can deteriorate patients’ quality of life (QoL). Differences ex